The recent findings of a huge study may erase some concerns about a pain reliever that has long been saddled with a worrisome reputation: celecoxib (Celebrex). While all nonsteroidal anti-inflammatory drugs (NSAIDs) carry a warning that users have an increased risk for heart attacks and strokes, celecoxib is closely linked to two similar drugs that were taken off the market due to concerns about their cardiovascular safety. However, the new research suggests that celecoxib may not be more dangerous than other NSAIDs, and might even be safer in some important ways. Continue reading Celecoxib: Not So Hard on the Heart?
The Food and Drug Administration (FDA) has approved etanercept-szzs (brand name: Erelzi), a biosimilar form of etanercept (Enbrel), to treat rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis as well as plaque psoriasis. Earlier this year, infliximab-dyyb (Inflectra), a biosimilar version of infliximab (Remicade), became the first FDA-approved biosimilar for inflammatory types of arthritis in the U.S.
Continue reading FDA Approves Second Arthritis Biosimilar – Biosimilar Version of Drug Enbrel
Graci is 11-years-old and stands just five feet tall. But don’t let her age and size fool you. She’s wiser than most and has the stature of a superstar.
Graci has battled juvenile polyarticular arthritis for most of her life. As a member of our Advocate program, she has been very active fighting on behalf of people with arthritis.
Continue reading CBS’s Sunday Morning Features 11-year-old Arthritis Foundation Advocate, Graci Diggs
Last week more than 400 pediatric rheumatologists, researchers, fellows, patients, parents and industry representatives, along with Arthritis Foundation staff members and volunteers, came together for the 2016 Annual Scientific Meeting of CARRA, the Childhood Arthritis and Rheumatology Research Alliance. Held in Toronto, Canada, this was CARRA’s largest annual meeting to date, with participants from renowned institutions across the United States and abroad.
For nearly 70 years, the Arthritis Foundation has been committed to serving families affected by juvenile arthritis and other childhood rheumatic diseases. We’ve supported CARRA since it formed more than a decade ago, and today our partnership is stronger than ever. Both CARRA and the Arthritis Foundation are working to improve treatments and outcomes for the estimated 300,000 children in the U.S. who live with arthritis and related conditions. Together, we are creating a more unified and powerful research and advocacy community by leveraging physicians, researchers and staff from both organizations.
Continue reading Pediatric Rheumatologists, Researchers and Patients Unite in Toronto to Change the Future of Living With Childhood Arthritis
With the cost of college tuition and other academic fees constantly on the rise, getting free money to pursue a degree can be a real blessing and honor. To make educational and career goals easier to obtain, our friends at AbbVie have established the AbbVie Rheumatology Scholarship, open only to exceptional students living with one or more of four rheumatic diseases.
Applicants must submit proof of being diagnosed with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis or ankylosing spondylitis. Also required is proof of enrolling in an accredited, U.S.-based institution for the 2016-17 academic year.
Continue reading $15,000 Scholarship Opportunity for Young People With Arthritis
Michael Ortman, Arthritis Foundation board chair, knows all too well how juvenile arthritis (JA) can impact a family for a lifetime.
When his son, Daniel, was 11 years old, he began complaining of pain in his foot and ankle. The Ortmans took Daniel to numerous doctors to determine the cause, and after he was diagnosed with a bone scan, Mike and his wife, Kate, were told that Daniel had JA – and that it was spreading to other joints in his body. His parents watched as Daniel went from an active, tree-climbing, independent child to a boy who needed a wheelchair and assistance performing everyday tasks.
Now 27, Daniel continues to struggle with mobility, and has spent most of the last three years homebound. Although he has experienced some recent victories, he still struggles from the ongoing physical and mental challenges of arthritis.
Kids get arthritis, too! And we at the Arthritis Foundation are dedicated to being their champions. According to the Centers for Disease Control and Prevention, an estimated 300,000 children in the U.S. have been diagnosed with juvenile arthritis (JA) and other childhood rheumatic conditions. It’s likely that many more kids are affected by rheumatic diseases and don’t even know it.
We are boldly leading the fight for families living with this mysterious disease. To help them cope, we now offer a unique package of support for young patients and their families.
The daily struggles of a child with juvenile arthritis (JA) can be heart-wrenching and frightening. Painful and debilitating flares, infusions and injections, teasing and bullying.
In the United States, about 300,000 children have arthritis, and we at the Arthritis Foundation are committed to bringing awareness to this group of diseases and the struggles of families living with the disease during July – JA Awareness month – and all year long.